Challenges Associated with Metal Chelation Therapy in Alzheimer’s Disease

A close association between brain metal dishomeostasis and the onset and/or progression of Alzheimer’s disease (AD)
has been clearly established in a number of studies, although the underlying biochemical mechanisms remain obscure. This
observation renders chelation therapy an attractive pharmacological option for the treatment of this disease. However, a number
of requirements must be fulfilled in order to adapt chelation therapy to AD so that the term “metal targeted strategies” seems now
more appropriate. Indeed, brain metal redistribution rather than brain metal scavenging and removal is the major goal of this type
of intervention. The most recent developments in metal targeted strategies for AD will be discussed using, as useful examples,
clioquinol, curcumin, and epigallocatechin, and the future perspectives will also be outlined.